Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States

**Background:** Gastroesophageal reflux disease (GERD) is a risk factor for Barrett’s esophagus (BE) and BE-related neoplasia (BERN). **Objectives:** This study aimed to evaluate healthcare resource utilization (HRU) and costs associated with GERD, BE, and BERN in the United States. **Methods:** Adu...

Full description

Saved in:
Bibliographic Details
Main Authors: Prateek Sharma, Gary W. Falk, Menaka Bhor, A. Burak Ozbay, Dominick Latremouille-Viau, Annie Guerin, Sherry Shi, Margaret M. Elvekrog, Paul Limburg
Format: Article
Language:English
Published: Columbia Data Analytics, LLC 2023-03-01
Series:Journal of Health Economics and Outcomes Research
Online Access:https://doi.org/10.36469/001c.68191
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823860358604914688
author Prateek Sharma
Gary W. Falk
Menaka Bhor
A. Burak Ozbay
Dominick Latremouille-Viau
Annie Guerin
Sherry Shi
Margaret M. Elvekrog
Paul Limburg
author_facet Prateek Sharma
Gary W. Falk
Menaka Bhor
A. Burak Ozbay
Dominick Latremouille-Viau
Annie Guerin
Sherry Shi
Margaret M. Elvekrog
Paul Limburg
author_sort Prateek Sharma
collection DOAJ
description **Background:** Gastroesophageal reflux disease (GERD) is a risk factor for Barrett’s esophagus (BE) and BE-related neoplasia (BERN). **Objectives:** This study aimed to evaluate healthcare resource utilization (HRU) and costs associated with GERD, BE, and BERN in the United States. **Methods:** Adult patients with GERD, nondysplastic BE (NDBE), and BERN (including indefinite for dysplasia \[IND\], low-grade dysplasia \[LGD\], high-grade dysplasia \[HGD\] or esophageal adenocarcinoma \[EAC\]), were identified from a large US administrative claims database, the IBM Truven Health MarketScan® databases (Q1/2015-Q4/2019). Patients were categorized into the corresponding mutually exclusive EAC-risk/diagnosis cohorts based on the most advanced stage from GERD to EAC using diagnosis codes in medical claims. Disease-related HRU and costs (2020 USD) were calculated for each cohort. **Results:** Patients were categorized into the following EAC-risk/diagnosis cohorts: 3 310 385 into GERD, 172 481 into NDBE, 11 516 into IND, 4332 into LGD, 1549 into HGD, and 11 676 into EAC. Disease-related annual mean number of inpatient admissions, office visits, and emergency department visits by cohort were 0.09, 1.45, and 0.19 for GERD; 0.08, 1.55, and 0.10 for NDBE; 0.10, 1.92, and 0.13 for IND; 0.09, 2.05, and 0.10 for LGD; 0.12, 2.16, and 0.14 for HGD; and 1.43, 6.27, and 0.87 for EAC. Disease-related annual mean total healthcare costs by cohort were $6955 for GERD, $8755 for NDBE, $9675 for IND, $12 241 for LGD, $24 239 for HGD, and $146 319 for EAC. **Discussion:** Patients with GERD, BE, and BERN had important HRU and costs, including inpatient admissions and office visits. As patients progressed to more advanced stages, there was substantially higher disease-related resource utilization, with associated costs being 16 times higher in patients with EAC than those with NDBE. **Conclusions:** Findings suggest the need for early identification of high-risk individuals prior to progression to EAC to potentially improve clinical and economic outcomes in this population.
format Article
id doaj-art-8f6873c3d63c4affbd3f961ddbcfe609
institution Kabale University
issn 2327-2236
language English
publishDate 2023-03-01
publisher Columbia Data Analytics, LLC
record_format Article
series Journal of Health Economics and Outcomes Research
spelling doaj-art-8f6873c3d63c4affbd3f961ddbcfe6092025-02-10T16:12:50ZengColumbia Data Analytics, LLCJournal of Health Economics and Outcomes Research2327-22362023-03-01101Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United StatesPrateek SharmaGary W. FalkMenaka BhorA. Burak OzbayDominick Latremouille-ViauAnnie GuerinSherry ShiMargaret M. ElvekrogPaul Limburg**Background:** Gastroesophageal reflux disease (GERD) is a risk factor for Barrett’s esophagus (BE) and BE-related neoplasia (BERN). **Objectives:** This study aimed to evaluate healthcare resource utilization (HRU) and costs associated with GERD, BE, and BERN in the United States. **Methods:** Adult patients with GERD, nondysplastic BE (NDBE), and BERN (including indefinite for dysplasia \[IND\], low-grade dysplasia \[LGD\], high-grade dysplasia \[HGD\] or esophageal adenocarcinoma \[EAC\]), were identified from a large US administrative claims database, the IBM Truven Health MarketScan® databases (Q1/2015-Q4/2019). Patients were categorized into the corresponding mutually exclusive EAC-risk/diagnosis cohorts based on the most advanced stage from GERD to EAC using diagnosis codes in medical claims. Disease-related HRU and costs (2020 USD) were calculated for each cohort. **Results:** Patients were categorized into the following EAC-risk/diagnosis cohorts: 3 310 385 into GERD, 172 481 into NDBE, 11 516 into IND, 4332 into LGD, 1549 into HGD, and 11 676 into EAC. Disease-related annual mean number of inpatient admissions, office visits, and emergency department visits by cohort were 0.09, 1.45, and 0.19 for GERD; 0.08, 1.55, and 0.10 for NDBE; 0.10, 1.92, and 0.13 for IND; 0.09, 2.05, and 0.10 for LGD; 0.12, 2.16, and 0.14 for HGD; and 1.43, 6.27, and 0.87 for EAC. Disease-related annual mean total healthcare costs by cohort were $6955 for GERD, $8755 for NDBE, $9675 for IND, $12 241 for LGD, $24 239 for HGD, and $146 319 for EAC. **Discussion:** Patients with GERD, BE, and BERN had important HRU and costs, including inpatient admissions and office visits. As patients progressed to more advanced stages, there was substantially higher disease-related resource utilization, with associated costs being 16 times higher in patients with EAC than those with NDBE. **Conclusions:** Findings suggest the need for early identification of high-risk individuals prior to progression to EAC to potentially improve clinical and economic outcomes in this population.https://doi.org/10.36469/001c.68191
spellingShingle Prateek Sharma
Gary W. Falk
Menaka Bhor
A. Burak Ozbay
Dominick Latremouille-Viau
Annie Guerin
Sherry Shi
Margaret M. Elvekrog
Paul Limburg
Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States
Journal of Health Economics and Outcomes Research
title Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States
title_full Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States
title_fullStr Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States
title_full_unstemmed Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States
title_short Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States
title_sort healthcare resource utilization and costs among patients with gastroesophageal reflux disease barrett s esophagus and barrett s esophagus related neoplasia in the united states
url https://doi.org/10.36469/001c.68191
work_keys_str_mv AT prateeksharma healthcareresourceutilizationandcostsamongpatientswithgastroesophagealrefluxdiseasebarrettsesophagusandbarrettsesophagusrelatedneoplasiaintheunitedstates
AT garywfalk healthcareresourceutilizationandcostsamongpatientswithgastroesophagealrefluxdiseasebarrettsesophagusandbarrettsesophagusrelatedneoplasiaintheunitedstates
AT menakabhor healthcareresourceutilizationandcostsamongpatientswithgastroesophagealrefluxdiseasebarrettsesophagusandbarrettsesophagusrelatedneoplasiaintheunitedstates
AT aburakozbay healthcareresourceutilizationandcostsamongpatientswithgastroesophagealrefluxdiseasebarrettsesophagusandbarrettsesophagusrelatedneoplasiaintheunitedstates
AT dominicklatremouilleviau healthcareresourceutilizationandcostsamongpatientswithgastroesophagealrefluxdiseasebarrettsesophagusandbarrettsesophagusrelatedneoplasiaintheunitedstates
AT annieguerin healthcareresourceutilizationandcostsamongpatientswithgastroesophagealrefluxdiseasebarrettsesophagusandbarrettsesophagusrelatedneoplasiaintheunitedstates
AT sherryshi healthcareresourceutilizationandcostsamongpatientswithgastroesophagealrefluxdiseasebarrettsesophagusandbarrettsesophagusrelatedneoplasiaintheunitedstates
AT margaretmelvekrog healthcareresourceutilizationandcostsamongpatientswithgastroesophagealrefluxdiseasebarrettsesophagusandbarrettsesophagusrelatedneoplasiaintheunitedstates
AT paullimburg healthcareresourceutilizationandcostsamongpatientswithgastroesophagealrefluxdiseasebarrettsesophagusandbarrettsesophagusrelatedneoplasiaintheunitedstates